Search Results - "Santiago, Linda"

1384 LNK101, a highly differentiated T-cell engager (TCE) targeting CD3 and mesothelin (MSLN) in solid tumors by Santiago, Linda, Bandaranayake, Ashok, Correnti, Colin, Lin, Ida, Chan, Man Kid, Delbecq, Scott, Clarke, Midori, Carter, Jane, Gruff, Eric, Bracken, William, Meininger, David, Hausman, Diana, Mehlin, Christopher

“…BackgroundMSLN is a membrane protein overexpressed by many cancers with limited expression in normal tissues. One challenge in developing MSLN-targeted…”
Get full text

Exposure-response analysis for selection of optimal dosage regimen of anifrolumab in patients with systemic lupus erythematosus by Chia, Yen Lin, Santiago, Linda, Wang, Bing, Kuruvilla, Denison, Wang, Shiliang, Tummala, Raj, Roskos, Lorin

“…The randomized, double-blind, phase 2 b MUSE study evaluated the efficacy and safety of the type I IFN receptor antibody anifrolumab (300 mg or 1000 mg every 4…”
Get full text

Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up by Kreitman, Robert J., Tallman, Martin S., Robak, Tadeusz, Coutre, Steven, Wilson, Wyndham H., Stetler-Stevenson, Maryalice, FitzGerald, David J., Santiago, Linda, Gao, Guozhi, Lanasa, Mark C., Pastan, Ira

“…Anti-CD22 moxetumomab pasudotox achieved 46% complete remissions (CRs) in previously reported phase 1 testing in relapsed/refractory hairy cell leukemia (HCL;…”
Get full text

Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers by Johnson, Melissa Lynne, Dy, Grace K., Mamdani, Hirva, Dowlati, Afshin, Schoenfeld, Adam Jacob, Pacheco, Jose Maria, Sanborn, Rachel E., Menon, Smitha Patiyil, Santiago, Linda, Yaron, Yifah, Beltran, Himisha

“…8566 Background: HPN328 is a delta like canonical Notch ligand 3 (DLL3)-targeting T-cell engager (TCE) derived from the TriTAC platform, designed to minimize…”
Get full text

Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers by Tummala, Raj, Rouse, Tomas, Berglind, Anna, Santiago, Linda

“…ObjectivesTo compare the pharmacokinetics (PK), safety and tolerability of subcutaneous (SC) and intravenous anifrolumab, an anti–type I interferon receptor…”
Get full text

HPN328, a Trispecific T Cell-Activating Protein Construct Targeting DLL3-Expressing Solid Tumors by Molloy, Mary E, Aaron, Wade H, Barath, Manasi, Bush, Mabel C, Callihan, Evan C, Carlin, Kevin, Cremin, Michael, Evans, Thomas, Guerrero, Maria G, Hemmati, Golzar, Hundal, Avneel S, Lao, Llewelyn, Laurie, Payton, Lemon, Bryan D, Lin, S J, O'Rear, Jessica, Patnaik, Purbasa, Sotelo Rocha, Sony, Santiago, Linda, Strobel, Kathryn L, Valenzuela, Laura B, Wu, Chi-Heng, Yu, Stephen, Yu, Timothy Z, Anand, Banmeet S, Law, Che-Leung, Sun, Liping L, Wesche, Holger, Austin, Richard J

“…Delta-like ligand 3 (DLL3) is expressed in more than 70% of small cell lung cancers (SCLCs) and other neuroendocrine-derived tumor types. SCLC is highly…”
Get more information

Efficacy and safety of moxetumomab pasudotox (moxe) in adult patients (pts) with relapsed/refractory hairy cell leukemia (HCL) in relation to drug exposure, baseline disease burden, and immunogenicity by Kuruvilla, Denison, Chia, Yen Lin, Santiago, Linda, Balic, Kemal, Yao, Nai-Shun, Kreitman, Robert J., Pastan, Ira, Li, Xia, Liang, Meina, Tseng, Chih-Ming, Faggioni, Raffaella, Roskos, Lorin

“…Abstract only…”
Get full text

PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC) by Huddart, Robert A., Siefker-Radtke, Arlene O., Balar, Arjun Vasant, Bilen, Mehmet Asim, Powles, Thomas, Bamias, Aristotelis, Castellano, Daniel, Khalil, Maged F., Van Der Heijden, Michiel Simon, Koshkin, Vadim S, Pook, David William, Ozguroglu, Mustafa, Santiago, Linda, Saab, Rabih, Li, Pao-Chen, Tagliaferri, Margit Cecile, Lin, Wei, Tagliaferri, Mary Ann, Loriot, Yohann

“…Abstract only TPS589 Background: Checkpoint inhibitors can achieve durable responses in cis-ineligible 1L mUC. However, use is restricted to patients whose…”
Get full text

Pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of moxetumomab pasudotox (Moxe), an immunotoxin targeting CD22, in adult patients (Pts) with relapsed or refractory hairy cell leukemia (HCL) by Balic, Kemal, Standifer, Nathan, Santiago, Linda, Kuruvilla, Denison, Yao, Nai-Shun, Kreitman, Robert J., Pastan, Ira, Li, Xia, Liang, Meina, Vainshtein, Inna, Tseng, Chih-Ming, Faggioni, Raffaella, Roskos, Lorin

“…Abstract only…”
Get full text

PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer by Huddart, Robert A, Siefker-Radtke, Arlene O, Balar, Arjun V, Bilen, Mehmet A, Powles, Thomas, Bamias, Aristotelis, Castellano, Daniel, Khalil, Maged F, Van Der Heijden, Michiel S, Koshkin, Vadim S, Pook, David W, Özgüroğlu, Mustafa, Santiago, Linda, Zhong, Bob, Chien, David, Lin, Wei, Tagliaferri, Mary A, Loriot, Yohann

“…The choice of first-line therapy for patients with metastatic urothelial cancer (mUC) is based on cisplatin-eligibility and programmed death-ligand 1 (PD-L1)…”
Get full text

Relación entre la idoneidad del estudiante para aprender en línea y la evaluación de usabilidad de los cursos en línea by Santiago Ramos, Linda N

“…El propósito de esta investigación es examinar la relación existente entre la idoneidad estudiantil para aprender en línea y su evaluación de la usabilidad del…”
Get full text

La relación afectiva entre maestro y estudiante: Implicaciones en la deserción escolar by Santiago-Dones, Linda I

“…School dropouts in the intermediate grades are becoming more acute in Puerto Rico, according to the different investigations. School desertion is a complex…”
Get full text